Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;5(1):70-4.
doi: 10.7774/cevr.2016.5.1.70. Epub 2016 Jan 27.

Augmented immune responses in pigs immunized with an inactivated porcine reproductive and respiratory syndrome virus containing the deglycosylated glycoprotein 5 under field conditions

Jung-Ah Lee  1 , Nak-Hyung Lee  2 , Joong-Bok Lee  2 , Seung-Yong Park  2 , Chang-Seon Song  2 , In-Soo Choi  2 , Sang-Won Lee  2
Affiliations

Augmented immune responses in pigs immunized with an inactivated porcine reproductive and respiratory syndrome virus containing the deglycosylated glycoprotein 5 under field conditions

Jung-Ah Lee et al. Clin Exp Vaccine Res. 2016 Jan.

Abstract

Purpose: Porcine reproductive and respiratory syndrome virus (PRRSV) leads to major economic losses in the swine industry. Vaccination is the most effective method to control the disease by PRRSV.

Materials and methods: In this study, the efficacy of a glycoprotein (GP) 5-modified inactivated vaccine was investigated in pigs. The study was performed in three farms: farm A, which was porcine reproductive and respiratory syndrome (PRRS)-negative, farm B (PRRS-active), which showed clinical signs of PRRS but had not used vaccines, and farm C (PRRS-stable), which had a history of endemic PRRS over the past years, but showed no more clinical signs after periodic administration of modified live virus vaccine.

Results: The inactivated vaccine induced great enhancement in serum neutralizing antibody titer, which was sufficient to protect pigs from further infections of PRRSV in a farm where pre-existing virus was circulating.

Conclusion: These results indicated that vaccination with the inactivated vaccine composed of viruses possessing deglycosylated GP5 would provide enhanced protection to pigs from farms suffering from endemic PRRSV.

Keywords: Inactivated vaccines; Neutralization test; Porcine reproductive and respiratory syndrome virus.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1
Serum neutralizing antibody titer of pigs from three different farms post-vaccination with the inactivated vaccine. Farm A was porcine reproductive and respiratory syndrome-negative; farm B showed clinical signs of porcine reproductive and respiratory syndrome virus, but had not used modified live virus (MLV) vaccine; farm C had used periodic MLV vaccine in pigs since 1 week of age. WPV, weeks post-vaccination. Significant difference (*p<0.05 and **p<0.01).
See this image and copyright information in PMC

References

    1. Neumann EJ, Kliebenstein JB, Johnson CD, et al. Assessment of the economic impact of porcine reproductive and respiratory syndrome on swine production in the United States. J Am Vet Med Assoc. 2005;227:385–392. - PubMed
    1. Charerntantanakul W. Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects. World J Virol. 2012;1:23–30. - PMC - PubMed
    1. Nielsen HS, Oleksiewicz MB, Forsberg R, Stadejek T, Botner A, Storgaard T. Reversion of a live porcine reproductive and respiratory syndrome virus vaccine investigated by parallel mutations. J Gen Virol. 2001;82(Pt 6):1263–1272. - PubMed
    1. Murtaugh MP, Stadejek T, Abrahante JE, Lam TT, Leung FC. The ever-expanding diversity of porcine reproductive and respiratory syndrome virus. Virus Res. 2010;154:18–30. - PubMed
    1. Bassaganya-Riera J, Thacker BJ, Yu S, Strait E, Wannemuehler MJ, Thacker EL. Impact of immunizations with porcine reproductive and respiratory syndrome virus on lymphoproliferative recall responses of CD8+ T cells. Viral Immunol. 2004;17:25–37. - PubMed